[Featured Stock] Antiphos Rises 10% on News of COVID-19 Antigen Rapid Test Kit Export Approval
[Asia Economy Reporter Minji Lee] AndyForce is on the rise following news that it has obtained export approval from the Ministry of Food and Drug Safety (MFDS) for its COVID-19 antigen rapid diagnostic kit.
At 9:28 a.m. on the 16th, AndyForce was trading at 9,490 KRW on the KOSDAQ market, up 9.84% from the previous session.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- Court Partially Grants Samsung Electronics' Injunction to Prohibit Industrial Action... 100 Million Won Penalty Per Day for Violations
- [US-China Summit] China to Purchase $17 Billion in US Agricultural Products Annually...Real Gains for Beijing
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Earlier that morning, AndyForce announced that after receiving European certification (CE) for its antigen rapid diagnostic kit in September, it has now obtained export approval domestically. The company plans to pursue approval from the U.S. Food and Drug Administration (FDA) in the future.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
